
- Volume 0 0
RADAR Detects Drug Reactions
The Research on Adverse DrugEvents and Reports (RADAR) systemhas successfully uncovered previouslyunknown, serious reactions among 14commonly used drugs, according to areport published in the Journal of theAmerican Medical Association (May 4,2005). Investigators have found thatin the past 6 years the drug-monitoringsystem went beyond the FDA'sinformation gathered after new drugsentered the marketplace.
The FDA's reporting system relieson information voluntarily submittedby pharmaceutical companies andphysicians through the Adverse EventsReports System and the Manufacturers'User and Device Experience. Theresearchers noted that the flaw inthese systems is that they require siftingthrough huge amounts of data touncover safety issues.
The RADAR system is formatted differently.Instead of relying on hugedatabases, it starts with 25 physiciansat academic medical centers located inChicago, Albuquerque, San Antonio,Salt Lake City, and New Orleans. Thesephysicians have their clinical "ears tothe ground." If something has potential,word goes out to a broad group ofclinicians, and researchers search forother cases.
To date, RADAR has detected 16serious, often deadly, and previouslyunknown types of drug and medicaldevice reactions connected with 14commonly used drugs. The medicationsinclude the anemia drug epoetin,the cancer drug gemcitabine, and thedrug ticlopidine, used to lower the incidenceof strokes. The system has pickedup serious adverse drug reactions in954 patients. Of these patients, 169, or18%, died. Although some of the datacame from the FDA's own files, RADARwas able to find a pattern of adversereactions faster than the FDA.
Timeliness is imperative in savinglives, said study author Charles Bennett,MD, PhD. Every year adversedrug reactions account for 100,000fatalities. The FDA has mandated thatmanufacturers add 45 drug reactionsto package inserts. Identifying morethan half of these reactions, however,took more than 7 years after the drugshad been approved. "Our goal is todecrease that to 11/2 to 2 years," said Dr.Bennett.
Articles in this issue
almost 21 years ago
A Pharmacist's Guide to OTC Therapy: Vaginal Yeast Infection Productsalmost 21 years ago
Consensus Guidelines for Hormone Therapyalmost 21 years ago
OTC Therapies for Allergic Rhinitisalmost 21 years ago
A Pharmacist's Guide to OTC Therapy: Menstrual Pain Productsalmost 21 years ago
A Pharmacist's Guide to OTC Therapy: Calcium Supplementsalmost 21 years ago
RxPRODUCT NEWS: PROFILE: Boniva (ibandronate)almost 21 years ago
PhRMA Revamps Web Sitealmost 21 years ago
Ovulation-Prediction Testing Kits: A Woman's Choicealmost 21 years ago
Examining Antithrombotic Therapyalmost 21 years ago
Web Site Expands ServicesNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


































































































































